Association between pneumococcal vaccination and cardiovascular outcomes: A systematic review and meta-analysis of cohort studies

European Journal of Preventive Cardiology

Volumn 22, Issue 9, 2015, Pages 1185-1199

  Vlachopoulos, Charalambos V ^a   Terentes Printzios, Dimitrios G ^a   Aznaouridis, Konstantinos A ^a   Pietri, Panagiota G ^a   Stefanadis, Christodoulos I ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

cardiovascular disease; cardiovascular mortality; meta analysis; myocardial infarction; Pneumococcal vaccination; stroke

Indexed keywords

PNEUMOCOCCUS VACCINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; FOLLOW UP; HEART INFARCTION; HUMAN; INFORMATION RETRIEVAL; LUNG DISEASE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STREPTOCOCCUS PNEUMONIA; SYSTEMATIC REVIEW; VACCINATION; AGE; AGED; CARDIOVASCULAR DISEASES; COMMUNITY-ACQUIRED INFECTIONS; COMPLICATION; FEMALE; MALE; MICROBIOLOGY; MIDDLE AGED; MORTALITY; ODDS RATIO; PATHOGENICITY; PNEUMONIA, PNEUMOCOCCAL; PROTECTION; RISK FACTOR; STREPTOCOCCUS PNEUMONIAE; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS; TREATMENT OUTCOME; VACCINATION;

EID: 84938871745     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487314549512     Document Type: Review

References (63)

1. Hoyert DL, Xu J. Deaths: preliminary data for 2011. Natl Vital Stat Rep 2012; 61: 4. National Center for Health Statistics. Centers for Disease Control and Prevention, http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61-06.pdf (accessed 1 January 2014).
2. Cillóniz C, Ewig S, Polverino E,. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011; 66: 340-346.
3. Woodhead M,. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J Suppl 2002; 36: 20s-27s.
4. Jackson ML, Neuzil KM, Thompson WW,. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004; 39: 1642-1650.
5. Fry AM, Shay DK, Holman RC,. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA 2005; 294: 2712-2719.
6. Corrales-Medina VF, Musher DM, Wells GA,. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012; 125: 773-781.
7. Corrales-Medina VF, Suh KN, Rose G,. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med 2011; 8: e1001048-e1001048.
8. Corrales-Medina VF, Musher DM, Shachkina S,. Acute pneumonia and the cardiovascular system. Lancet 2013; 381: 496-505.
9. Vlachopoulos C, Dima I, Aznaouridis K,. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation 2005; 112: 2193-2200.
10. Jackson LA, Pneumococcal polysaccharide vaccines. In: Plotkin SA, Orenstein WA, Offit PA, (eds). Vaccines, 6th edn. London: W.B. Saunders Elsevier, 2013, pp. 542-572.
11. Jackson LA, Yu O, Heckbert SR,. Vaccine Safety Datalink Study Group. Influenza vaccination is not associated with a reduction in the risk of recurrent coronary events. Am J Epidemiol 2002; 156: 634-640.
12. Tseng HF, Slezak JM, Quinn VP,. Pneumococcal vaccination and risk of acute myocardial infarction and stroke in men. JAMA 2010; 303: 1699-1706.
13. Hung IF, Leung AY, Chu DW,. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis 2010; 51: 1007-1016.
14. Gilbertson DT, Guo H, Arneson TJ,. The association of pneumococcal vaccination with hospitalization and mortality in hemodialysis patients. Nephrol Dial Transplant 2011; 26: 2934-2939.
15. Chan TC, Hung IF, Luk JK,. Prevention of mortality and pneumonia among nursing home older adults by dual pneumococcal and seasonal influenza vaccination during a pandemic caused by novel pandemic influenza A (H1N1). J Am Med Dir Assoc 2012; 13: 698-703.
16. Chang YC, Chou YJ, Liu JY,. Additive benefits of pneumococcal and influenza vaccines among elderly persons aged 75 years or older in Taiwan-a representative population-based comparative study. J Infect 2012; 65: 231-238.
17. Zahid M, Singla I, Good CB,. Associations between Pneumococcal Vaccination and Adverse Outcomes in Patients with Suspected Acute Coronary Syndrome. Adv Infect Dis 2012; 2: 122-134.
18. Johnstone J, Loeb M, Teo KK,. Ongoing Telmisartan Alone and in combination with Ramipril Global EndPoint Trial (ONTARGET); Telmisartan Randomized Assessment Study in ACE Intolerant subjects with cardiovascular Disease (TRANSCEND) investigators. Influenza vaccination and major adverse vascular events in high-risk patients. Circulation 2012; 126: 278-286.
19. Eurich DT, Johnstone JJ, Minhas-Sandhu JK,. Pneumococcal vaccination and risk of acute coronary syndromes in patients with pneumonia: population-based cohort study. Heart 2012; 98: 1072-1077.
20. Chen LF, Chen HP, Huang YS,. Pneumococcal pneumonia and the risk of stroke: a population-based follow-up study. PLoS One 2012; 7: e51452-e51452.
21. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T,. EPIVAC Study Group. Ineffectiveness of pneumococcal vaccination in cardiovascular prevention: the CAPAMIS study. JAMA Intern Med 2013; 173: 1918-1920.
22. Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T,. EPIVAC Research Group. Evaluating the clinical effectiveness of pneumococcal vaccination in preventing myocardial infarction: the CAPAMIS study, three-year follow-up. Vaccine 2014; 32: 252-257.
23. Smeeth L, Thomas SL, Hall AJ,. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351: 2611-2618.
24. Meyers DG, Beahm DD, Jurisich PD,. Influenza and pneumoccocal vaccinations fail to prevent myocardial infarction. Heart Drug 2004; 4: 96-100.
25. Lamontagne F, Garant MP, Carvalho JC,. Pneumococcal vaccination and risk of myocardial infarction. CMAJ 2008; 179: 773-777.
26. Siriwardena AN, Gwini SM, Coupland CA,. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. CMAJ 2010; 182: 1617-1623.
27. Siriwardena AN, Asghar Z, Coupland CAC,. Influenza and pneumococcal vaccination and risk of stroke or transient ischaemic attack-matched case control study. Vaccine 2014; 32: 1354-1361.
28. Fisman DN, Abrutyn E, Spaude KA,. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 2006; 42: 1093-1101.
29. Viasus D, Garcia-Vidal C, Manresa F,. Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. J Infect 2013; 66: 27-33.
30. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T,. EPIVAC Study Group. Clinical effectiveness of pneumococcal vaccination against acute myocardial infarction and stroke in people over 60 years: the CAPAMIS study, one-year follow-up. BMC Public Health 2012; 12: 222-222.
31. Vila-Corcoles A, Hospital-Guardiola I, Ochoa-Gondar O,. Rationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke. BMC Public Health 2010; 10: 25-25.
32. Hedlund J, Christenson B, Lundbergh P,. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up. Vaccine 2003; 21: 3906-3911.
33. Christenson B, Pauksen K, Sylvan SP,. Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity. Virol J 2008; 5: 52-52.
34. Bond TC, Spaulding AC, Krisher J,. Mortality of dialysis patients according to influenza and pneumococcal vaccination status. Am J Kidney Dis 2012; 60: 959-965.
35. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T,. EPIVAC Research Group. Evaluating clinical effectiveness of pneumococcal vaccination in preventing stroke: the CAPAMIS Study, 3-Year follow-up. J Stroke Cerebrovasc Dis 2014; 23: 1577-1484.
36. Moberley S, Holden J, Tatham DP,. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1: CD000422-CD000422.
37. Huss A, Scott P, Stuck AE,. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180: 48-58.
38. Stroup DF, Berlin JA, Morton SC,. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 283: 2008-2012.
39. Liberati A, Altman DG, Tetzlaff J,. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W65-94.
40. Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK,. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes 2013; 6: 99-109.
41. Vlachopoulos C, Aznaouridis K, Stefanadis C,. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55: 1318-1327.
42. Vlachopoulos C, Aznaouridis K, O'Rourke MF,. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010; 31: 1865-1871.
43. Wells GA, Shea B, OConnell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, www.ohri.ca/programs/clinical-epidemiology/oxford.asp (accessed 1 January 2014).
44. Atkins D, Best D, Briss PA,. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490-1490.
45. Higgins JP, Thompson SG, Deeks JJ,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
46. Altman DG, Bland JM,. Interaction revisited: the difference between two estimates. BMJ 2003; 326: 219-219.
47. Duval S, Tweedie R,. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455-463.
48. Borenstein M, Hedges L, Higgins J,. Comprehensive Meta Analysis, Version 2. Englewood, NJ: Biostat, 2005.
49. Fedson DS, Liss C,. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 2004; 22: 927-946.
50. Vila-Córcoles A,. Vaccinate your child and save its grandparents from a heart attack? Current perspectives in antipneumococcal vaccination. J Intern Med 2009; 266: 432-444.
51. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance report, Emerging Infections Program Network, Streptococcus pneumoniae, http://www.cdc.gov/abcs/reports-findings/survreports/spneu12.html (2012, accessed 1 January 2014).
52. Griffin MR, Zhu Y, Moore MR,. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013; 369: 155-163.
53. Menéndez R, Sahuquillo-Arce JM, Reyes S,. Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. Chest 2012; 141: 1537-1545.
54. Musher DM, Rueda AM, Kaka AS,. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007; 45: 158-165.
55. Corrales-Medina VF, Serpa J, Rueda AM,. Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. Medicine (Baltimore) 2009; 88: 154-159.
56. Wang CC, Peng CL, Wang GJ,. Pneumococcal pneumonia and the risk of acute coronary syndrome: a population-based cohort study. Int J Cardiol 2013; 168: 4480-4481.
57. Binder CJ, Hörkkö S, Dewan A,. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003; 9: 736-743.
58. Thygesen K, Alpert JS, Jaffe AS, et al. Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Katus HA, Lindahl B, Morrow DA, et al. Third universal definition of myocardial infarction. Circulation 2012; 126: 2020-2035.
59. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61: 816-819.
60. Perk J, de Backer G, Gohlke H,. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol 2012; 19: 585-667.
61. Yancy CW, Jessup M, Bozkurt B,. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: e240-327.
62. Hebert K, Marzouka G, Arcement L,. Prevalence of vaccination rates in systolic heart failure: a prospective study of 549 patients by age, race, ethnicity, and sex in a heart failure disease management program. Congest Heart Fail 2010; 16: 278-283.
63. Gohlke H,. Is it worth offering cardiovascular disease prevention to the elderly? Eur J Prev Cardiol 2013; 20: 121-126.